Superbugs and Superdrugs 2020
: 30 Mar 2020 - 1 Apr 2020
: London, United Kingdom
Type: Conference, Workshop
As one of the most impactful pharmaceuticals for maintaining public health, antibiotics have been around since the early 20th century and have since shown a need for significant progress in recent years. This is mainly due to their broad and indiscriminate use which has slowly given birth to multi - to extensively drug-resistant bacteria rendering our current last-resort antibiotic arsenal, including colistin, carbapenems, 3rd and 4th generation cephalosporins, useless.
This year’s event aims to showcase a suite of sessions focused on novel drugs and approaches, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR.
It is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020, along with leaders from the pharmaceutical industry, academia, regulatory and funding bodies, and public-private partnerships to discuss the way forward.
Highlights of this year's conference will include:
- Discuss the new classes of non-antibiotic antibacterial proteins: Colicins and Colicin-like Bacteriocins from Nomad Bioscience
- Gain valuable insight towards fighting severe and resistant infections through neutralising bacterial virulence effectors from Combioxin
- Examine a UK project looking at novel value assessment and reimbursement for novel antimicrobials from NICE/Manchester University NHS Foundation Trust
- Explore direct lytic agents (DLAs) and their potential as a successful disruptive anti-infective technology with Contrafect
- Evaluate the utility of machine learning and AI in antibiotic drug discovery with Oxford Drug Design
Register by 31st January and save £100
Two workshops on Wednesday 1st April will focus on:
- Development of non-traditional agents and alternatives to antibiotics
- Anti-microbial resistance and pathogenic fungi